Podcasts about Amyloidosis

This week, Jonathan is joined by Xavier Leleu, world-renowned expert in multiple myeloma, Waldenström's macroglobulinemia, and amyloidosis. The pair discuss groundbreaking advances in clinical trials and the future of myeloma immunotherapy.   Timestamps:  (00:00)-Introduction  (00:59)-Clinical trial breakthroughs in transplant-ineligible myeloma  (03:38)-Minimal residual disease: a key endpoint   (05:21)-Rethinking therapeutic strategies in myeloma   (10:58)-Challenges in late-line myeloma therapies   (13:54)-T-cell-engaging bispecific antibodies   (17:41)-Waldenström's macroglobulinemia and amyloidosis  (21:50)-What's next in multiple myeloma treatment?  (24:43)-Xavier's three wishes for healthcare   

Dr. Galati is back in the studio tonight with two guests. He starts with a quick chat about colon cancer now that we are into March. The disease of the night is amyloidosis. Dr. Galati has two colleagues, Dr. Barry Trachtenberg and Dr. Mahwash Kassi join him to talk all about it.

Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826241296676

Today's podcast features a discussion with experts Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Ashutosh Wechalekar,... The post Post-ASH amyloidosis highlights: the ANDROMEDA trial, risk stratification, value of MRD, & more! appeared first on VJHemOnc.

Dave Logan is the long-time radio voice of the Denver Broncos. This is his weekly podcast offering his knowledge and insight on the Broncos and everything in the world of sports. For more on The Dave Logan Podcast, check out our webpage at thedaveloganpodcast.com and our twitter handle @daveloganpod 

Discover the intricacies of cardiac amyloidosis, an often-overlooked condition that significantly impacts heart health. Join Dr. Nirav Shah as he explains the effects of amyloid proteins on heart function, the demographics most at risk, and why this condition should be on your radar.

Heart disease remains one of the leading causes of death—but breakthroughs in science are rewriting the narrative. Join us as Dr. Kevin Alexander, a Assistant Professor of Cardiovascular Medicine at Stanford University, takes us on a journey through the frontlines of heart health innovation. Discover transthyretin amyloid cardiomyopathy (ATTR-CM), a condition disproportionately affecting older African Americans, and learn how cutting-edge treatments are offering new hope. Through a discussion on risk factors, symptoms, and barriers to care, Dr. Alexander highlights the actionable steps to improve awareness and access in underserved communities. Read Transcript CME Information: https://stanford.cloud-cme.com/medcastepisode98 Claim CE and MOC: https://stanford.cloud-cme.com/Form.aspx?FormID=3160

In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including:Early results with teclistamab combined with anti-CD38 therapyReal-world data with teclistamab including its use after other BCMA-targeted therapiesTalquetamab as bridging therapy to BCMA-targeted CAR T-cell therapyEvaluation of prophylactic tocilizumab for cytokine-release syndrome associated with bispecific antibody therapyPresenter:Shaji K. Kumar, MDMark and Judy Mullins Professor of Hematologic MalignanciesConsultant, Division of HematologyProfessor of MedicineChair, Myeloma, Amyloidosis and Dysproteinemia GroupResearch Chair, Division of HematologyAssociate Chair for Research, Department of MedicineMayo ClinicRochester, MinnesotaLink to full program:https://bit.ly/40bjFCZ

Art Still's body felt the ravages of playing professional football for twelve years, but when he suffered atrial fibrillation, he sought medical attention.  His doctor suggested he undergo a genetic test, which revealed he had the variant for a disease known as amyloidosis.  While not cancer, if left untreated in a timely manner, it can lead to various types of blood cancer.  Early detection, periodic shots and medication will not get rid of the variant, but they will team up to keep from developing into blood cancer.  Art pays attention to diet, exercise and the right amount of sleep, and says he enjoys a healthy lifestyle.   Art accepted carpal tunnel syndrome, trigger finger and a torn biceps muscle as the byproducts of his NFL career, but atrial fibrillation was different. Through the National Football League Players Association, he went to New Orleans for a thorough physical and mental examination. His doctor suggested Art undergo a genetic test to see if Art had a variant for amyloidosis, a disease which if left untreated can be linked to various types of blood cancer.  A brother of his had undergone heart replacement, and another brother needs one.  That combined with the suggestion from the doctor was enough to get Art to take the test, and sure enough, it indicated he had the V122I variant, which Art says affects one in 25 African-Americans.   He is now on a regimen that includes medications and periodic shots.  It will not rid Art of the variant, but keeps it at bay so that it doesn't become cancerous, affecting other organs like kidneys and the brain.   Art Still wants to maximize awareness of amyloidosis, and has established a website that provides a wealth of information on the subject so that like Art, others can get in front of the disease.   Additional Resources:   Art's website: https://www.amyloidosisarmy.org          

Host: Saurabh Malhotra, MD, MPH Guest: Kevin Alexander, MD Guest: Tawfiq Al-lahham, MD Guest: Sarah Cuddy, MD Guest: Angela Dispenzieri, MD Guest: Anita D'Souza, MD Guest: Foluso Fakorede, MD Guest: Mazen Hanna, MD Guest: Isabelle Lousada Guest: Ahmad Masri, MD, MS Guest: Mathew S. Maurer, MD Guest: Matthew Parker, MD Guest: Frederick Ruberg, MD Guest: Andrew Staron, MD Guest: Prem Soman, MD, PhD Guest: Jonathan Wall, PhD Guest: Ashutosh Wechalekar, MBBS, MD Guest: Panithaya Chareonthaitawee, MD The Masterclass in Cardiac Amyloidosis: Disease Spectrum, Diagnosis and Management will consist of four virtual live sessions on March 7-9, 2025. The case-based sessions will provide an in-depth discussion of cardiac amyloidosis and its pathogenesis, diagnostic techniques and pitfalls, management strategies, mechanisms to facilitate early diagnosis, treatment and management, and challenging case studies presented by leading internationally recognized experts in transthyretin cardiac amyloidosis.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/QTM865. CME/NCPD/CPE credit will be available until January 22, 2026.Don't Fail Them Now: Bridging Diagnostic and Treatment Gaps in Transthyretin Cardiac Amyloidosis[JAC_Logo] In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from BridgeBio Pharma, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/QTM865. CME/NCPD/CPE credit will be available until January 22, 2026.Don't Fail Them Now: Bridging Diagnostic and Treatment Gaps in Transthyretin Cardiac Amyloidosis[JAC_Logo] In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from BridgeBio Pharma, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/QTM865. CME/NCPD/CPE credit will be available until January 22, 2026.Don't Fail Them Now: Bridging Diagnostic and Treatment Gaps in Transthyretin Cardiac Amyloidosis[JAC_Logo] In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from BridgeBio Pharma, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/QTM865. CME/NCPD/CPE credit will be available until January 22, 2026.Don't Fail Them Now: Bridging Diagnostic and Treatment Gaps in Transthyretin Cardiac Amyloidosis[JAC_Logo] In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from BridgeBio Pharma, Inc.Disclosure information is available at the beginning of the video presentation.

Commentary by Dr. Sabahat Bokhari.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/QTM865. CME/NCPD/CPE credit will be available until January 22, 2026.Don't Fail Them Now: Bridging Diagnostic and Treatment Gaps in Transthyretin Cardiac Amyloidosis[JAC_Logo] In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from BridgeBio Pharma, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/QTM865. CME/NCPD/CPE credit will be available until January 22, 2026.Don't Fail Them Now: Bridging Diagnostic and Treatment Gaps in Transthyretin Cardiac Amyloidosis[JAC_Logo] In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from BridgeBio Pharma, Inc.Disclosure information is available at the beginning of the video presentation.

Join CardioNerds Heart Failure Section Chair Dr. Jenna Skowronski, episode lead Dr. Apoorva Gangavelli, and expert faculty Dr. Ronald Witteles as they discuss the Nex-Z trial. This was a phase 1, open-label trial investigating nex-z, a CRISPR-Cas9-based treatment, in 36 patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The primary objectives were aimed at studying the safety and pharmacodynamics of this novel gene-based treatment modality. This episode dives into the nuances of the data, future directions for investigation, and future clinical implications. CardioNerds Journal Club PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! References - The Nex-Z Trial Fontana, M., Solomon, S. D., Kachadourian, J., Walsh, L., Rocha, R., Lebwohl, D., Smith, D., Täubel, J., Gane, E. J., Pilebro, B., Adams, D., Razvi, Y., Olbertz, J., Haagensen, A., Zhu, P., Xu, Y., Leung, A., Sonderfan, A., Gutstein, D. E., & Gillmore, J. D. (2024). CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2412309

Commentary by Dr.  Jian'an Wang

Join us as Paul and Watto reflect on the past year, discussing some favorite insights gained covering a range of topics, including dental pain management, cardiac amyloidosis, the impact of continuous glucose monitoring on diabetes care, the complexities of diagnosing primary hyperparathyroidism, hepatitis B screening and vaccination, GLP-1 agonists, travel medicine, endometriosis, rhinitis, and recurrent UTIs.  Plus, we feature listener voicemails sharing their favorite episodes and why they love the Curbsiders! No CME for this episode, but claim CME for past shows at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Introduction and Year-End Reflections 02:59 Picks of the Year 05:53 Dental Pain and Oral Care Insights 10:25 Cardiac Amyloidosis 14:33 Listener mail- diabetes 16:33 Neck Pain 19:08 Continuous Glucose Monitoring in Diabetes 23:57 Hyperparathyroidism 30:48  Hepatitis B  34:01 Listener mail- obesity 36:14 Travel Medicine: Malaria, Diarrhea, and Vaccination 40:38 Endometriosis 46:08 Rhinitis and Environmental Allergies 49.24  Recurrent UTIs 55:08 Reflections on Nine Years of Curbsiders Credits Written, Produced, and hosted by: Matthew Watto MD, FACP; Paul Williams MD, FACP Cover Art: Matthew Watto MD, FACP Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Molly Heublein MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Sponsor: AquaTru Today listeners receive 20% OFF any AquaTru purifier! Just go to AquaTru.com and enter code “CURB“ at checkout.   Sponsor: Freed Visit Freed.ai. Use code CURB50 to get $50 off your first month. Sponsor: Quince Go to Quince.com/curb for 365-day returns, plus free shipping on your order! 

Recent headlines claim that eating enough protein—about “two and a half chicken breasts” worth daily—could reduce the risk of dementia. While protein is indeed critical for brain health, there's more to the story.In this hot health topic episode, I explore why chicken may not be the ideal protein source for everyone. Modern farming practices have raised questions about potential risks associated with certain proteins, highlighting the importance of understanding where our food comes from and how it impacts overall health.Join me as I discuss the latest research, uncover safer protein options, and share practical tips for supporting brain health through supplements, diet, and lifestyle.Supplements Featured In This Episode:• Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement • Accelerated Cogniblast® https://www.acceleratedhealthproducts.com/products/cogniblast-nootropic• Accelerated Methylene Blue™ https://www.acceleratedhealthproducts.com/products/accelerated-methylene-blue-supplement Not sure what food to eat and avoid? This guide is for you.⬇️

Host: John Russell, MD Guest: Noel Dasgupta, MD, FACC Guest: Sami Khella, MD Amyloidosis, often unrecognized, misdiagnosed, and either inappropriately treated or undertreated, is a collection of diseases caused by the misfolding of proteins that aggregate into insoluble amyloid fibrils and deposit in tissues. There are two prominent forms of amyloidosis misfolding of light chain proteins (AL amyloidosis) and transthyretin protein misfolding (ATTR amyloidosis). In this program, two experts in amyloidosis, cardiologist Dr. Noel Dasgupta and neurologist Dr. Sami Khella, will explain the pathophysiology of amyloidosis, describe the prognosis for patients, discuss timely patient screening and diagnostic testing, and provide updated treatment options.

CME credits: 0.50 Valid until: 13-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/best-practices-for-identifying-diagnosing-and-treating-transthyretin-amyloidosis-attr-pn-and-attr-cm/26799/ Amyloidosis, often unrecognized, misdiagnosed, and either inappropriately treated or undertreated, is a collection of diseases caused by the misfolding of proteins that aggregate into insoluble amyloid fibrils and deposit in tissues. There are two prominent forms of amyloidosis misfolding of light chain proteins (AL amyloidosis) and transthyretin protein misfolding (ATTR amyloidosis). In this program, two experts in amyloidosis, cardiologist Dr. Noel Dasgupta and neurologist Dr. Sami Khella, will explain the pathophysiology of amyloidosis, describe the prognosis for patients, discuss timely patient screening and diagnostic testing, and provide updated treatment options. =

In this episode of Neurology Minute, Dr. Stacey Clardy discusses Amyloidosis. Show reference: https://doi.org/10.1111/imj.15974     

Charles, a recently retired cardiologist of 53 years, speaks with David Rintell, Head of Patient Advocacy at BridgeBio, and Mandy Rohrig, Director of Patient Advocacy at BridgeBio Gene Therapy, about how his unexpected early diagnosis of ATTR-CM likely impacted the trajectory of his disease. Dr. Jonathan Fox, President and Chief Medical Officer of cardiorenal programs at BridgeBio, explains how ATTR affects the heart and peripheral nervous system, and the importance of early diagnosis.   For years, Charles suffered from numbness and tingling in both wrists and hands. Eventually, when the pain became so severe that operating a mouse for 10 to 15 minutes was difficult, he was referred to a hand surgeon who recommended carpal tunnel surgery. Preparing for the surgery, Charles recalled reading a medical journal article that indicated 10% of people who underwent carpel tunnel surgery had positive tissue biopsy indicative of ATTR-CM. He requested that his surgeon perform a biopsy and shortly thereafter received his diagnosis. The transition from doctor to patient was not easy for Charles. However, he feels fortunate to be a cardiologist, to have read and remembered the article, requested a biopsy, and received the diagnosis more quickly than many others who live with ATTR. “I have three passions: running, traveling, and teaching," Charles shared. The early diagnosis has allowed him to continue to live a full, active life, running nearly daily as he has for the past 45 years. Charles, now 86, continues to serve others, spending his retirement teaching and mentoring health care providers around the country about ATTR and volunteering for amyloidosis advocacy organizations.

In this episode of Talk With a Doc, we delve into a remarkable story of resilience and innovation. Howard "H" White, the man instrumental in building the iconic Jordan Brand at Nike, Inc., is now championing a new cause--the Howard "H" White Center for Cardiac Amyloidosis. Join host Jennifer Semenza as she speaks with Dr. Jacob Abraham, section head for advanced heart failure, and Dr. Jenna Kay, medical director of the new Howard “H” White Center for Cardiac Amyloidosis, both from the Providence Heart Institute. They are joined by center namesake, Howard "H" White, Vice President for NIKE Inc.'s Jordan Brand, and heart transplant recipient. The Howard “H” White Center was established in honor of White, who relied on the expert care at Providence Heart Institute  in 2017 when he was diagnosed with cardiac amyloidosis—a progressive disease that hampers the heart's ability to pump effectively. This often under-diagnosed condition deserves significant attention, prompting Providence to launch this new center to support early detection, research, and treatment.With NBA legend Michael Jordan donating $1 million in support – along with donations from many patients and leaders in entertainment, sports and business – the center aims to improve healthcare equity, particularly as cardiac amyloidosis disproportionately affects the Black community.Tune in as our panel of experts shines a light on this vital health issue and the new initiatives at the Howard "H" White Center for Cardiac Amyloidosis.To learn more about the Howard "H" White Center for the Cardiac Amyloidosis, visit: Providence Heart Institute: Howard White Center 

Cardiac amyloidosis used to be a disease with no treatment and poor outcomes. Now we have new treatment options, new ways to make the diagnosis, and much improved outcomes. Unfortunately, this disease is still very under-diagnosed, often until patients are in the late stages of the disease. Dr. Parker shares a brief update on how cardiac amyloidosis develops, and how it's diagnosed and treated in the modern era.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TDS865. CME credit will be available until October 23, 2025.TTRansforming the TTReatment of ATTR: A Guide to the Pathophysiology, Diagnosis, and Emerging Treatment Strategies for ATTR Amyloidosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TDS865. CME credit will be available until October 23, 2025.TTRansforming the TTReatment of ATTR: A Guide to the Pathophysiology, Diagnosis, and Emerging Treatment Strategies for ATTR Amyloidosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TDS865. CME credit will be available until October 23, 2025.TTRansforming the TTReatment of ATTR: A Guide to the Pathophysiology, Diagnosis, and Emerging Treatment Strategies for ATTR Amyloidosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TDS865. CME credit will be available until October 23, 2025.TTRansforming the TTReatment of ATTR: A Guide to the Pathophysiology, Diagnosis, and Emerging Treatment Strategies for ATTR Amyloidosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TDS865. CME credit will be available until October 23, 2025.TTRansforming the TTReatment of ATTR: A Guide to the Pathophysiology, Diagnosis, and Emerging Treatment Strategies for ATTR Amyloidosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TDS865. CME credit will be available until October 23, 2025.TTRansforming the TTReatment of ATTR: A Guide to the Pathophysiology, Diagnosis, and Emerging Treatment Strategies for ATTR Amyloidosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure information is available at the beginning of the video presentation.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on DPD quantification correlates with extracellular volume and disease severity in wild-type transthyretin cardiac amyloidosis.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on impact of the noninvasive diagnostic algorithm on clinical presentation and prognosis in cardiac amyloidosis.

JACC: Heart Failure Social Media Editor Giorgia Benzoni, MD, discusses a recently published Leading Edge Commentary comparing the pathophysiological differences between ATTR and AL cardiac amyloidosis and implications for therapy.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances discusses a recently published original research paper on an impact of case and control selection on training artificial intelligence screening of cardiac amyloidosis.

Cardiac Amyloidosis: No Longer Rare and Untreatable!      Guest: Omar F. Abou Ezzeddine, M.D., M.S. Hosts: Malcolm R. Bell, M.D.   Transthyretin amyloid cardiomyopathy (ATTR-CM), once considered rare, is more prevalent than previously thought. Diagnosing ATTR-CM is particularly important because there are now highly effective, specific therapies for ATTR-CM. In this podcast, we will provide a contemporary review of the diagnostic and therapeutic approach to patients with ATTR-CM in the current era.   Topics Discussed: When to suspect the disease & who to screen for ATTR-CM? How to diagnose and prognosticate ATTR-CM in the current era? Provide an overview of current and emerging therapies for managing ATTR-CM.   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

Ron Witteles, MD, and and Andrew Nguyen, MD, discuss the study design and findings of HELIOS-B, and clinical impact of vutrisiran in transthyretin amyloid cardiomyopathy.

6th ESC 2024: Vutrisiran

The MUSC Health Amyloidosis Center of Excellence offers a multidisciplinary approach to cardiac amyloidosis, with expertise from specialists such as Dr. Jan Griffin. Treatments have greatly advanced in recent years for this rare and life-threatening condition. In this episode, Dr. Griffin discusses these advancements and therapies available to treat this condition as well as ongoing research on this condition.

Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research that was presented at the 2024 European Society of Cardiology annual meeting. Visit NEJM.org to read the latest research.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances discusses a recently published original research paper on Age- and Sex-Related Differences in Patients with Wild-Type Transthyretin Amyloidosis

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZHC865. CME credit will be available until July 15, 2025.TTRemendous Advances in Transthyretin Amyloidosis Treatment: What Neurologists Need to Know In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZHC865. CME credit will be available until July 15, 2025.TTRemendous Advances in Transthyretin Amyloidosis Treatment: What Neurologists Need to Know In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure information is available at the beginning of the video presentation.

Listen as Dr. London Smith (.com) and his producer Cameron discuss Renal Amyloidosis with special guest Kip Blair (Trey Murray). Not so boring! https://www.patreon.com/join/jockdocpodcast Hosts: London Smith, Cameron Clark. Guest: Trey Murray. Produced by: Dylan Walker Created by: London Smith

Sean joins David Rintell, Head of Patient Advocacy at BridgeBio, and Mandy Rohrig, Director of Patient Advocacy at BridgeBio Gene Therapy to share his journey with ATTR. In this episode, Sean describes his initial symptoms, which included carpal tunnel syndrome and numbness in his foot and ankle, the misdiagnosis he experienced, and his eventual diagnosis at the Cleveland Clinic in Abu Dhabi. While the diagnosis was a relief it was also difficult to accept and took an emotional toll on him and those around him. Sean has found this to be a common experience of many diagnosed with ATTR. Since Sean's form of ATTR is hereditary, various members of his family have also been tested. Sean also highlights the positive changes in his life, including meeting his wife, Robin, discovering a talent for drawing, and becoming a public speaker about ATTR. Jonathan Fox, President and Chief Medical Officer of cardiorenal programs at BridgeBio, joins us again to give a medical introduction to ATTR. On this episode, Jonathan highlights the differences of the ATTR T80 variant. Previously, we learned that ATTR amyloidosis is caused by the dissociation of a protein called transthyretin, or TTR, that changes its shape and forms into fibrous clumps. These clumps of misshapen protein are deposited into various organs and peripheral nerves, including the heart, which can cause them to function abnormally. Jonathan explains the possible origin of the T80 variant and how the T80 variant symptoms can differ from ATTR-CM.   To learn more about living with amyloidosis visit Mackenzie's Mission, www.mm713.org

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

What is the natural history and cardiovascular burden of the V142I transthyretin variant among US Black individuals who carry this variant? Senthil Selvaraj, MD, MS, MA, from Duke University, and Scott D. Solomon, MD, from Brigham and Women's Hospital, discuss this and more with JAMA Executive Editor Gregory Curfman, MD. Related Content: Cardiovascular Burden of the V142I Transthyretin Variant Addressing Health Disparities—The Case for Variant Transthyretin Cardiac Amyloidosis Grows Stronger Heart Failure in African American Individuals, Version 2.0 Cardiac Amyloidosis Due to Transthyretin Protein

The clinical picture of an underrecognized disease Amyloidosis demystified. Learn the clinical clues that suggest possible amyloidosis and how to order the correct tests to diagnose this disease. We are joined by Dr. Michelle Kittleson who shows us the ropes of treating fibril accumulation, @MKittlesonMD (Cedars Sinai).  Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Introduction Case Presentation: Mr. Smith Differential Diagnosis of Heart Failure with Preserved Ejection Fraction Understanding Amyloidosis Clinical Clues and Red Flags for Amyloidosis Physical Examination Findings Workup for Amyloidosis Treatment Options AL Amyloidosis and Hematologist's Role ATTR Amyloidosis and Cardiologist's Role Other Therapies for TTR Amyloidosis Therapy on the Horizon Cost and Access to Tafamidis Alternative Therapies and Supplements Monitoring and Side Effects of Tafamidis Symptomatic Management and Anticoagulation Take Home Points Credits Written and Produced by; Deborah Gorth, MD, PhD Infographic and Cover Art: Meryl Gorth, RD, MPH and Deborah Gorth, MD, PhD Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Sai S. Achi MD MBA Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Michelle Kittleson, MD, PhD Sponsor: Panacea  Visit panaceafinancial.com today to open your free account. Sponsor: Grammarly  Make a bigger impact at work with Grammarly. Sign up and download for FREE at grammarly.com/PODCAST Sponsor: Rocket Money  Stop wasting money on things you don't use. Cancel your unwanted subscriptions by going to RocketMoney.com/CURB.